Restoration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa

Journal of Immunology

Volumn 177, Issue 7, 2006, Pages 4627-4635

  Kinoshita, Manabu ^a   Shinomiya, Nariyoshi ^a   Ono, Satoshi ^a   Tsujimoto, Hironori ^a   Kawabata, Toshinobu ^a   Matsumoto, Atsushi ^a   Hiraide, Hoshio ^a   Seki, Shuhji ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 18;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BURN; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAM NEGATIVE INFECTION; HOST RESISTANCE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INFECTION SENSITIVITY; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURVIVAL RATE;

EID: 33749118273     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.7.4627     Document Type: Article

References (56)

1. Richard, P., R. Le Floch, C. Chamoux, M. Pannier, E. Espaze, and H. Richet. 1994. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J. Infect. Dis. 170: 377-383.
2. Gang, R. K., R. L. Bang, S. C. Sanyal, E. Mokaddas, and A. R. Lari. 1999. Pseudomonas aeruginosa septicaemia in burns. Burns 25: 611-616.
3. Taneja, N., R. Emmanuel, P. S. Chari, and M. Sharma. 2004. A prospective study of hospital-acquired infections in burn patients at a tertiary care referral centre in North India. Burns 30: 665-669.
4. Ami, K., M. Kinoshita, A. Yamauchi, T. Nishikage, Y. Habu, N. Shinomiya, T. Iwai, H. Riraide, and S. Seki. 2002. IFN-γ production from liver mononuclear cells of mice in burn injury as well as in postburn bacterial infection models and the therapeutic effect of IL-18. J. Immunol. 169: 4437-4442.
5. Kinoshita, M., S. Seki, S. Ono, N. Shinomiya, and H. Hiraide. 2004. Paradoxical effect of IL-18 therapy on the severe and mild Escherichia coli infections in burn-injured mice. Ann. Surg. 240: 313-320.
6. Suzuki, F., and R. B. Pollard. 1982. Mechanism for the suppression of γ-interferon responsiveness in mice after thermal injury. J. Immunol. 129: 1811-1815.
7. O'Suilleabhain, C., S. T. O'Sullivan, J. L. Kelly, J. Lederer, J. A. Mannick, and M. L. Rodrick. 1996. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery 120: 290-296.
8. O'Sullivan, S. T., and T. P. O'Connor. 1997. Immunosuppression following thermal injury: the pathogenesis of immunodysfunction. Br. J. Plast. Surg. 50: 615-623.
9. Goebel, A., E. Kavanagh, A. Lyons, I. B. Saporoschetz, C. Soberg, J. A. Lederer, J. A. Mannick, and M. L. Rodrick. 2000. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann. Surg. 231: 253-261.
10. Munster, A. M., H. C. Hoagland, and B. A. Pruitt, Jr. 1970. The effect of thermal injury on serum immunoglobulins. Ann. Surg. 172: 965-969.
11. Bjornson, A. B., W. A. Altemeier, and H. S. Bjornson. 1977. Changes in humoral components of host defense following burn trauma. Ann. Surg. 186: 88-96.
12. Bjornson, A. B., W. A. Altemeier, and H. S. Bjornson. 1980. Complement, opsonins, and the immune response to bacterial infection in burned patients. Ann. Surg. 191: 323-329.
13. Gelfand, J. A., M. Donelan, A. Hawiger, and J. F. Burke. 1982. Alternative complement pathway activation increases mortality in a model of burn injury in mice. J. Clin. Invest. 70: 1170-1176.
14. Gelfand, J. A., M. Donelan, and J. F. Burke. 1983. Preferential activation and depletion of the alternative complement pathway by burn injury. Ann. Surg. 198: 58-62.
15. Winkelstein, A. 1984. What are the immunological alterations induced by burn injury? J. Trauma 24: S72-S83.
16. Casadevall, A., and M. D. Scharff. 1995. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21: 150-161.
17. Barrington, R., M. Zhang, M. Fischer, and M. C. Carroll. 2001. The role of complement in inflammation and adaptive immunity. Immunol. Rev. 180: 5-15.
18. Kinoshita, M., N. Kuranaga, A. Matsumoto, S. Ono, N. Shinomiya, H. Hiraide, and S. Seki. 2006. Multiple interleukin-18 injections promote both mouse Th1 and Th2 responses after sublethal Escherichia coli infection. Clin. Exp. Immunol. 143: 41-49.
19. + B cells: the Ly-1 B lineage? Annu. Rev. Immunol. 6: 197-218.
20. Hardy, R. R., and K. Hayakawa. 1994. CD5 B cells, a fetal B cell lineage. Adv. Immunol. 55: 297-339.
21. Wells, S. M., A. B. Kantor, and A. M. Stall. 1994. CD43 (S7) expression identifies peripheral B cell subsets. J. Immunol. 153: 5503-5515.
22. Avrameas, S. 1991. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton.' Immunol. Today 12: 154-159.
23. Boes, M., A. P. Prodeus, T. Schmidt, M. C. Carroll, and J. Chen. 1998. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188: 2381-2386.
24. Seki, S., S. Osada, S. Ono, S. Aosasa, Y. Habu, T. Nishikage, H. Mochizuki, and H. Hiraide. 1998. Role of liver NK cells and peritoneal macrophages in γ interferon and interleukin-10 production in experimental bacterial peritonitis in mice. Infect. Immun. 66: 5286-5294.
25. Nakagawa, R., I. Nagafune, Y. Tazunoki, H. Ehara, H. Tomura, R. Iijima, K. Motoki, M. Kamishohara, and S. Seki. 2001. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α- galactosylceramide in mice. J. Immunol. 166: 6578-6584.
26. Berk, R. S., I. N. Montgomery, and L. D. Hazlett. 1988. Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa. Infect. Immun. 56: 3076-3080.
27. Horvat, R. T., M. Clabaugh, C. Duval-Jobe, and M. J. Parmely. 1989. Inactivation of human γ interferon by Pseudomonas aeruginosa proteases: elastase augments the effects of alkaline protease despite the presence of α 2-macroglobulin. Infect. Immun. 57: 1668-1674.
28. Parmely, M., A. Gale, M. Clabaugh, R. Horvat, and W. W. Zhou. 1990. Proteolytic inactivation of cytokines by Pseudomonas aeruginosa. Infect. Immun. 58: 3009-3014.
29. Kinoshita, M., S. Ono, and H. Mochizuki. 2000. Neutrophils mediate acute lung injury in rabbits: role of neutrophil elastase. Eur. Surg. Res. 32: 337-346.
30. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276.
31. Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol 19: 423-474.
32. Netea, M. G., G. Fantuzzi, B. J. Kullberg, R. J. L. Stuyt, E. J. Pulido, R. C. McIntyre, Jr., L. A. B. Joosten, J. W. M. Van der Meer, and C. A. Dinarello. 2000. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J. Immunol. 164: 2644-2649.
33. Leung, B. P., S. Culshaw, J. A. Gracie, D. Hunter, C. A. Canetti, C. Campbell, F. Cunha, F. Y. Liew, and I. B. McInnes. 2001. A role for IL-18 in neutrophil activation. J. Immunol. 167: 2879-2886.
34. Lynn, W. A., and J. Cohen. 1995. Adjunctive therapy for septic shock: a review of experimental approaches. Clin. Infect. Dis. 20: 143-158.
35. van Deuren, M., A. S. Dofferhoff, and J. W. van der Meer. 1992. Cytokines and the response to infection. J. Pathol. 168: 349-356.
36. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378: 88-91.
37. + T cells, IL-4 and STAT6. Nat. Immunol. 1: 132-137.
38. Munster, A. M., K. T. Moran, J. Thupari, M. Allo, and R. A. Winchurch. 1987. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. J. Burn Care Rehabil. 8: 376-380.
39. Glinz, W., P. J. Grob, U. E. Nydegger, T. Ricklin, F. Stamm, D. Stoffel, and A. Lasance. 1985. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med. 11: 288-294.
40. De Simone, C., G. Delogu, and G. Corbetta. 1988. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit. Care Med. 16: 23-26.
41. Pilz, G., R. Appel, E. Kreuzer, and K. Werdan. 1997. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 111: 419-426.
42. Pollack, M. 1983. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J. Infect. Dis. 147: 1090-1098.
43. Werdan, K. 2001. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Ther. Apher. 5: 115-122.
44. Werdan, K. 1999. Supplemental immune globulins in sepsis. Clin. Chem. Lab. Med. 37: 341-349.
45. Gupta, M., G. J. Noel, M. Schaefer, D. Friedman, J. Bussel, and R. Johann-Liang. 2001. Cytokine modulation with immune γ-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J. Clin. Immunol. 21: 193-199.
46. Takata, Y., S. Seki, H. Dobashi, S. Takeshita, K. Nakatani, Y. Kamezawa, H. Hiraide, I. Sekine, and S. Yoshioka. 1998. Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD). Clin. Exp. Immunol. 114: 311-319.
47. Mehal, W. Z., F. Azzaroli, and I. N. Crispe. 2001. Immunology of the healthy liver: old questions and new insights. Gastroenterology 120: 250-260.
48. Mackay, I. R. 2002. Hepatoimmunology: a perspective. Immunol. Cell Biol. 80: 36-44.
49. Kantor, A. B., and L. A. Herzenberg. 1993. Origin of murine B cell lineages. Annu. Rev. Immunol. 11: 501-538.
50. Cooper, N. R. 1985. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 37: 151-216.
51. Toliver-Kinsky, T. E., T. K. Varma, C. Y. Lin, D. N. Herndon, and E. R. Sherwood. 2002. Interferon-γ production is suppressed in thermally injured mice: decreased production of regulatory cytokines and corresponding receptors. Shock 18: 322-330.
52. Toliver-Kinsky, T. E., C. Y. Lin, D. N. Herndon, and E. R. Sherwood. 2003. Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice. Infect. Immun. 71: 3058-3067.
53. Pierangeli, S. S., H. C. Polk, Jr., M. J. Parmely, and G. Sonnenfeld. 1993. Murine interferon-γ enhances resistance to infection with strains of Pseudomonas aeruginosa in mice. Cytokine 5: 230-234.
54. Hazlett, L. D., M. M. Moon, A. Singh, R. S. Berk, and X. L. Rudner. 1991. Analysis of adhesion, piliation, protease production and ocular infectivity of several P. aeruginosa strains. Curr. Eye Res. 10: 351-362.
55. Frank, D. W., G. Nair, and H. P. Schweizer. 1994. Construction and characterization of chromosomal insertional mutations of the Pseudomonas aeruginosa exoenzyme S trans-regulatory locus. Infect. Immun. 62: 554-563.
56. Rutenfranz, I., and H. Kirchner. 1988. Pharmacokinetics of recombinant murine interferon-γ in mice. J. Interferon. Res. 8: 573-580.